Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study
- PMID: 35143325
- DOI: 10.1161/STROKEAHA.121.037541
Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study
Abstract
Background: A small randomized controlled trial suggested that dabigatran may be as effective as warfarin in the treatment of cerebral venous thrombosis (CVT). We aimed to compare direct oral anticoagulants (DOACs) to warfarin in a real-world CVT cohort.
Methods: This multicenter international retrospective study (United States, Europe, New Zealand) included consecutive patients with CVT treated with oral anticoagulation from January 2015 to December 2020. We abstracted demographics and CVT risk factors, hypercoagulable labs, baseline imaging data, and clinical and radiological outcomes from medical records. We used adjusted inverse probability of treatment weighted Cox-regression models to compare recurrent cerebral or systemic venous thrombosis, death, and major hemorrhage in patients treated with warfarin versus DOACs. We performed adjusted inverse probability of treatment weighted logistic regression to compare recanalization rates on follow-up imaging across the 2 treatments groups.
Results: Among 1025 CVT patients across 27 centers, 845 patients met our inclusion criteria. Mean age was 44.8 years, 64.7% were women; 33.0% received DOAC only, 51.8% received warfarin only, and 15.1% received both treatments at different times. During a median follow-up of 345 (interquartile range, 140-720) days, there were 5.68 recurrent venous thrombosis, 3.77 major hemorrhages, and 1.84 deaths per 100 patient-years. Among 525 patients who met recanalization analysis inclusion criteria, 36.6% had complete, 48.2% had partial, and 15.2% had no recanalization. When compared with warfarin, DOAC treatment was associated with similar risk of recurrent venous thrombosis (aHR, 0.94 [95% CI, 0.51-1.73]; P=0.84), death (aHR, 0.78 [95% CI, 0.22-2.76]; P=0.70), and rate of partial/complete recanalization (aOR, 0.92 [95% CI, 0.48-1.73]; P=0.79), but a lower risk of major hemorrhage (aHR, 0.35 [95% CI, 0.15-0.82]; P=0.02).
Conclusions: In patients with CVT, treatment with DOACs was associated with similar clinical and radiographic outcomes and favorable safety profile when compared with warfarin treatment. Our findings need confirmation by large prospective or randomized studies.
Keywords: anticoagulants; contraindications; dabigatran; hemorrhage; venous thrombosis.
Comment in
-
ACTION-CVT: Are the Findings ACTIONable?Stroke. 2022 Mar;53(3):739-741. doi: 10.1161/STROKEAHA.122.038564. Epub 2022 Feb 10. Stroke. 2022. PMID: 35143324 No abstract available.
Similar articles
-
Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial.JAMA Neurol. 2019 Dec 1;76(12):1457-1465. doi: 10.1001/jamaneurol.2019.2764. JAMA Neurol. 2019. PMID: 31479105 Free PMC article. Clinical Trial.
-
Comparing the effectiveness and safety of direct oral anticoagulants and warfarin in patients with cerebral venous thrombosis: A real-world study.J Stroke Cerebrovasc Dis. 2025 Jun;34(6):108290. doi: 10.1016/j.jstrokecerebrovasdis.2025.108290. Epub 2025 Mar 14. J Stroke Cerebrovasc Dis. 2025. PMID: 40090604
-
Dabigatran etexilate versus warfarin in cerebral venous thrombosis in Chinese patients (CHOICE-CVT): An open-label, randomized controlled trial.Int J Stroke. 2024 Jul;19(6):635-644. doi: 10.1177/17474930241234749. Epub 2024 Feb 26. Int J Stroke. 2024. PMID: 38353219 Clinical Trial.
-
Direct Oral Anticoagulants Versus Vitamin K Antagonists in Cerebral Venous Thrombosis: A Systematic Review and Meta-Analysis.Stroke. 2022 Oct;53(10):3014-3024. doi: 10.1161/STROKEAHA.122.039579. Epub 2022 Aug 8. Stroke. 2022. PMID: 35938419
-
Apixaban for the treatment of cerebral venous thrombosis: A case series.J Neurol Sci. 2017 Oct 15;381:318-320. doi: 10.1016/j.jns.2017.09.007. Epub 2017 Sep 6. J Neurol Sci. 2017. PMID: 28991706 Review.
Cited by
-
Direct oral anticoagulants for treatment of venous thrombosis: illustrated review of appropriate use.Res Pract Thromb Haemost. 2024 Apr 26;8(4):102424. doi: 10.1016/j.rpth.2024.102424. eCollection 2024 May. Res Pract Thromb Haemost. 2024. PMID: 38812988 Free PMC article.
-
Functional outcome predictors and recanalization in cerebral venous thrombosis: A single-center cross-sectional study.Turk J Emerg Med. 2024 Oct 1;24(4):218-225. doi: 10.4103/tjem.tjem_65_24. eCollection 2024 Oct-Dec. Turk J Emerg Med. 2024. PMID: 39564436 Free PMC article.
-
Global Impact of the COVID-19 Pandemic on Cerebral Venous Thrombosis and Mortality.J Stroke. 2022 May;24(2):256-265. doi: 10.5853/jos.2022.00752. Epub 2022 May 31. J Stroke. 2022. PMID: 35677980 Free PMC article.
-
Cerebral venous thrombosis.Arq Neuropsiquiatr. 2022 May;80(5 Suppl 1):53-59. doi: 10.1590/0004-282X-ANP-2022-S108. Arq Neuropsiquiatr. 2022. PMID: 35976298 Free PMC article. Review.
-
Neurovascular complications of antiphospholipid syndrome: a narrative review.Arq Neuropsiquiatr. 2024 Dec;82(12):1-7. doi: 10.1055/s-0044-1793932. Epub 2024 Dec 10. Arq Neuropsiquiatr. 2024. PMID: 39658037 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous